Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study by Castillo-Mancilla, JR et al.
RESEARCH ARTICLE
Incomplete ART adherence is associated with higher
inflammation in individuals who achieved virologic suppression in
the START study
Jose R Castillo-Mancilla1§ , Andrew N Phillips2 , James D Neaton3, Jacqueline Neuhaus3, Shweta Sharma3,
Jason V Baker4,5, Simon Collins6, Sharon Mannheimer7, Sarah Pett2,8,9, Veronique Touzeau-R€omer10, Mark N
Polizzotto9, Jens D Lundgren11, and Edward M Gardner12 for the INSIGHT START Study Group
§Corresponding Author: Jose R Castillo-Mancilla, Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus. 12700
E 19th Ave., B168, Aurora, Colorado 80045. Tel: +303 724 4934. (jose.castillo-mancilla@ucdenver.edu)
Abstract
Introduction: Suboptimal ART adherence, despite HIV viral suppression, has been associated with chronic residual inflamma-
tion. Whether this association extends to individuals who initiate ART during early HIV infection remains unknown, which was
the objective of this study.
Methods: Plasma levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein, serum amyloid A protein (SAA), IL-27, sol-
uble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, D-dimer and the CD4+/CD8+ T-cell ratio, were
analysed at baseline and eight months after ART initiation in treatment-na€ıve participants with HIV and CD4+ T-cells >500
cells/mm3 enrolled in the immediate arm of START. Adherence was assessed by seven-day self-report. Multivariable linear
regression was utilized to analyse the association between ART adherence and each biomarker at the eight-month visit in par-
ticipants who achieved virologic suppression (<50 copies/mL).
Results: We evaluated 1627 participants (422 female) who achieved virologic suppression at the eight-month visit in the per-
iod between 2009 and 2013. Median (IQR) CD4+ T-cell count before ART was 651 (585, 769) cells/mm3. Incomplete adher-
ence was reported in 109 (7%) participants at the eight month visit. After adjusting for covariates, plasma IL-6 was 1.12 (95%
CI, 1.00 to 1.26; p = 0.047) fold higher in participants reporting incomplete versus 100% adherence. A similar association for
SAA was observed in an exploratory analysis (1.29 (95% CI 1.04 to 1.60); p = 0.02). No significant differences in other
biomarkers were observed.
Conclusions: Incomplete ART adherence was associated with higher IL-6 levels in individuals who achieved virologic suppres-
sion early after ART initiation in START. A potential similar association for SAA requires confirmation. These findings suggest a
role for identifying strategies to maximize ART adherence even during virologic suppression. ClinicalTrials.gov number:
NCT00867048.
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1 | INTRODUCTION
People living with HIV (PLHIV) continue to benefit from
antiretroviral therapy (ART) by preventing progression to
AIDS [1,2] and transmission to their partners [3]. However,
even in the setting of durable and sustained virologic suppres-
sion, PLHIV exhibit a phenotype of enhanced residual inflam-
mation, immune activation and coagulopathy [4] that is
predictive of serious non-AIDS events, including cardiovascular
disease, non-AIDS-related malignancies and all-cause mortality
[5-7]. A wide variety of potential mechanisms driving this phe-
nomenon have been proposed, including a high prevalence of
specific lifestyle behaviours such as smoking, illicit substance
use and obesity (all of which are common among PLHIV) [8,9],
and other factors such as microbial translocation [6], viral
co-infections (i.e. cytomegalovirus, hepatitis C virus) [10,11]
and HIV persistence in lymphoid tissues [12]. To date, efforts
to reverse residual inflammation and immune activation in
treated HIV infection (e.g. ART intensification, anti-inflamma-
tories, treating co-infections) have proven moderately
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successful [13-17]. Thus, a better understanding of the patho-
genesis of residual inflammation in HIV is needed in order to
develop effective interventions to reduce it and, potentially,
improve clinical outcomes.
Recent studies have demonstrated that suboptimal (i.e. less
than 100%) ART adherence could be a significant contributing
factor to the chronic residual inflammation, coagulopathy and
immune activation observed in PLHIV even if it is sufficient to
achieve and sustain plasma viral suppression through routinely
available assays [18-20]. These associations have been identi-
fied in PLHIV who are on chronic ART [18,20] and who have
recently initiated ART [19]. However, these studies included
participants who mostly initiated ART with advanced disease
(i.e. CD4+ T-cells <200 or <350 cells/mm3), based on the
treatment guidelines that were prevalent at the time. Whether
variations in ART adherence, beyond virologic suppression, are
also associated with heightened chronic residual inflammation,
immune activation and coagulopathy in early treated HIV
infection remains unknown.
To address the above-mentioned gap, we evaluated the
association between incomplete ART adherence with residual
inflammation, immune activation, coagulopathy and vascular
inflammation in treatment na€ıve PLHIV who initiated ART with
CD4+ T cells >500 cells/mm3 and achieved viral suppression
in the immediate arm of the Strategic Timing of Antiretroviral
Treatment (START) study. Based on our previous findings in
the SMART study [20], we hypothesized that plasma biomark-
ers of inflammation and coagulopathy (interleukin (IL)-6 and
D-dimer) would be higher in participants who achieved viro-
logic suppression but who reported incomplete versus 100%
adherence. In addition, we aimed to explore the association
between ART adherence and additional biomarkers of inflam-
mation, immune activation and vascular inflammation that
were assayed in the study population.
2 | METHODS
2.1 | Participants
Within the period between April 2009 through December
2013, the START study enrolled PLHIV who were 18 years of
age or older and who were ART na€ıve, had no history of an
AIDS-defining illness, and had CD4+ T cells >500 cells/mm3,
as previously reported [21]. To be included in this analysis,
participants were required to: (1) have been randomized to
the immediate treatment arm of START; (2) have achieved
viral suppression (<50 copies/mL) while on ART at the eight-
month visit, and; (3) have concomitant adherence data and
plasma biomarkers available at the eight-month visit. Each par-
ticipating site obtained study approval by their corresponding
local institutional review board or ethics committee, and writ-
ten informed consent was obtained from all participants prior
to any study procedures.
2.2 | Adherence assessment
ART adherence was measured by self-report at one, four and
eight months after ART initiation using a case report form
modelled after the Terry Beirn Community Programs for Clin-
ical Research on AIDS (CPCRA) Antiretroviral Medication
Self-Report Form 065-BAS-2, which uses a seven-day global
recall, where participants respond whether they took “all my
pills every day,” “most of my pills,” “about one-half of my pills,”
“very few of my pills,” or “none of my pills” for each specific pill
in their ART regimen. This adherence measure has been previ-
ously validated to predict viral suppression and the develop-
ment of viral rebound [22,23], and has been found to be
associated with heightened inflammation in participants with
viral suppression in the SMART study [20]. ART adherence at
the eight-month visit was labelled as “incomplete” if a partici-
pant reported any option other than taking “all of my pills
everyday” for any antiretroviral medication, and as “100%” if a
participant reported taking “all of my pills everyday” for all
ART medications, as previously described [20]. A supplemen-
tary sensitivity analysis, in which a participant was labelled to
have incomplete adherence if s/he reported <100% adherence
to any ART medication at any of the month one, four or eight
visits, was also performed to assess the robustness of our
findings.
2.3 | Biomarkers of systemic inflammation, vascular
inflammation and coagulopathy
Plasma samples were collected at baseline and at the eight-
month visit, and were stored at 70°C in a central laboratory.
In these samples, the following seven biomarkers reflecting (1)
systemic inflammation; (2) immune activation; (3) vascular
inflammation, and; (4) coagulopathy, were quantified by
blinded researchers: (1) IL-6, high-sensitivity C-reactive pro-
tein (hsCRP) and serum amyloid A protein (SAA); (2) IL-27; (3)
soluble intercellular adhesion molecule-1 (sICAM) and soluble
vascular adhesion molecule-1 (sVCAM), and; (4) D-dimer. IL-6
was quantified using a high-sensitivity enzyme-linked
immunosorbent assay (R&D Systems); IL-27 was quantified
using immunoassay (MesoScale, MSD); D-dimer was quantified
using the VIDAS system (BioMerieux); hsCRP, SAA, sICAM
and sVCAM were quantified using the Vascular Injury II
Panel (MesoScale, MSD), as previously described [24]. CD4+
and CD8+ T-cell subsets were determined by flow cytometry
at each site’s clinical laboratory.
2.4 | Statistical analysis
Baseline participant demographic characteristics were summa-
rized through the appropriate statistical measures. Adherence
was dichotomized as incomplete (<100%) or 100%. For two of
the biomarkers, IL-6 and D-dimer, there was a pre-specified
hypothesis that they would be associated with sub-optimal
adherence based on our previous work [20]. For the other
biomarkers, these were considered exploratory analyses. The
plasma concentrations of the biomarkers of inflammation,
immune activation, vascular inflammation and coagulopathy
(except the CD4+/CD8+ T-cell ratio) were natural log (ln)-
transformed in order to address data skewing. This was fol-
lowed by univariable and multivariable linear regression analy-
sis aimed at assessing the association between ART
adherence and the log-transformed biomarker concentrations
and the CD4+/CD8+ T-cell ratio at the eight-month visit in
participants who achieved virologic suppression to
<50 copies/mL. These analyses were adjusted for the follow-
ing baseline characteristics: sex, age, race, biomarker concen-
trations, level of education, HIV risk factor, region of
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enrolment, hepatitis B (defined as a positive hepatitis B sur-
face antigen) or hepatitis C (defined as a positive hepatitis C
antibody) co-infection, body mass index (BMI), and smoking.
These variables have previously been associated with inflam-
mation and coagulopathy in other studies [25,26], including
START [24], and/or with suboptimal adherence (e.g. African
American race [27], smoking [28], treatment in resource-lim-
ited settings [29]). Data are presented as fold differences in
biomarker concentrations and in the CD4+/CD8+ T-cell ratio
in individuals who reported incomplete versus 100% adher-
ence at the eight-month visit. All statistical analyses were per-
formed using SAS version 9.4. For the biomarkers included in
the exploratory analyses we used the non-parametric rank
sum method proposed by O’Brien [30,31], which provides a
single overall test of the null hypothesis of no difference
between the two adherence categories for these five biomark-
ers (excluded CD4+/CD8+ ratio). p-values were not adjusted
for multiple comparisons. A value of p < 0.05 was considered
to be statistically significant.
3 | RESULTS
3.1 | Study participants
From a total of 4684 participants enrolled from 215 sites in
35 countries in the START study, 2325 were randomized to
immediate ART. Of these, 1627 (70%) were virologically sup-
pressed to <50 copies/mL and had available adherence data
and biomarkers at the eight-month visit (Figure S1). Baseline
demographics included median age of 36 (interquartile range
(IQR) 29, 44) years, median CD4+ T-cell count of 651 (IQR
585, 769) cells/mm3 and a median HIV viral load of 13,123
(IQR 3331, 42,169) copies/mL before initiation of ART. Addi-
tional demographic characteristics of these participants upon
enrolment, according to adherence status, are presented in
Table 1.
3.2 | ART adherence
Among the 1627 participants included in the analysis, 109
(7%) reported incomplete adherence at the eight-month visit
(Table 1). Overall, the proportions of participants with incom-
plete adherence were similar according to ART class (Table 1).
Most (84%) participants in the incomplete adherence group
reported taking “most of my pills” for at least one of their
ART drugs, while 11 (10%) participants in this group reported
taking “none of my pills” for all their prescribed ART, 9 of
whom were on an efavirenz-based regimen. When the defini-
tion of incomplete adherence was expanded to include any
report of <100% adherence at any of the one, four or eight
months visits, the number of participants who had incomplete
adherence increased to 276 (17%) of the study population.
3.3 | Biomarkers of systemic inflammation, vascular
inflammation and coagulopathy
The plasma concentrations of biomarkers of inflammation,
immune activation, coagulopathy and vascular inflammation at
baseline and at the eight-month visit are presented in Table 2.
Overall, all the measured plasma biomarkers, except IL-27,
decreased between the baseline and the eight-month visits,
Table 1. Demographic characteristics of the immediate ART
arm participants in START with HIV RNA <50 copies/mL at the
eight-month visit, categorized by ART adherence at month 8
(n=1627)
Characteristic
Incomplete
adherence n=109
100%
Adherence
n=1518
n (%) or median (IQR)
Female sex 24 (22) 398 (26)
Age (years) 32 (27, 40) 36 (29, 44)
Time since diagnosis
(years)
1.1 (0.4, 3.0) 0.9 (0.3, 2.8)
Race
Black 31 (28) 448 (30)
Hispanic 24 (22) 191 (13)
Asian 10 (9) 139 (9)
White 35 (32) 683 (45)
Other 9 (8) 57 (4)
ART class at eight-month visita
NNRTI-based 77 (71) 1086 (72)
Efavirenz 74 (68) 1010 (67)
Rilpivirine 3 (3) 71 (5)
Nevirapine/
etravirine
0 (0) 5 (<1)
b/PI-based 22 (20) 337 (22)
Atazanavir 14 (13) 181 (12)
Darunavir 7 (6) 126 (8)
Lopinavir 1 (<1) 19 (1)
Fosamprenavir 0 (0) 11 (<1)
INSTI-basedb 9 (8) 76 (5)
Other/multiclass 1 (<1) 19 (1)
Education level
Less than high
school (less than
year 12 or “A”
level)
33 (30) 448 (30)
High school or
equivalent (year
12 or “A” level)
22 (20) 334 (22)
Completed
vocational
training
11 (10) 145 (10)
Some college/some
university
18 (17) 262 (17)
Bachelor’s/
university/TAFE
degree
20 (18) 248 (16)
Any post-graduate
education
5 (5) 81 (5)
HIV exposure
IDU 1 (1) 22 (1)
MSM 73 (67) 844 (56)
Heterosexual 33 (30) 572 (38)
Other 2 (2) 80 (5)
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showing statistically significant differences. The CD4+/CD8+
T-cell ratio increased from 0.66 (IQR 0.49, 0.89) at baseline
to 0.98 (IQR 0.74, 1.28) at the eight-month visit (p < 0.0001).
Baseline concentrations for all biomarkers were significantly
associated with the eight-month concentrations in an adjusted
analysis (range of correlation coefficients 0.40 to 0.78,
p < 0.0001; data not shown). There were no statistically sig-
nificant associations between baseline biomarker levels and
adherence at eight months (data not shown).
3.4 | Association between ART adherence and
biomarkers
The plasma concentrations of biomarkers of inflammation,
immune activation, vascular inflammation, coagulopathy and
the CD4+/CD8+ T-cell ratio, according to ART adherence cate-
gory in the participants who were virologically suppressed at
the eight-month visit, are shown in Table 3. Overall, the plasma
concentrations of biomarkers were higher among the partici-
pants who reported incomplete versus 100% adherence,
except for sVCAM and D-dimer (Table 3). In the univariable
analysis, plasma concentrations of IL-6 were 1.14 (95% CI,
1.00 to 1.31; p = 0.04) fold higher, and of D-dimer were 0.90
(95% CI, 0.79 to 1.02; p = 0.10) fold lower, in participants who
reported incomplete versus 100% adherence respectively
(Table 3). These remained statistically significant for IL-6 after
adjusting for sex, age, race, baseline biomarker concentrations,
level of education, HIV risk factor, region of enrolment, viral
hepatitis co-infection, BMI and smoking, with concentrations
that were 1.12 (95% CI, 1.00 to 1.26; p = 0.047) fold higher in
participants who reported incomplete versus 100% adherence
(Table 3). Considering the biomarkers in the exploratory analy-
sis, the p-value for the O’Brien global test was p = 0.35. In this
analysis, plasma concentrations of SAA were 1.25 (95% CI,
0.99 to 1.57; p = 0.06) fold higher in participants who
reported incomplete versus 100% adherence in the univariate
analysis, and became statistically significant after adjusting for
covariates, with 1.29 (95% CI, 1.04 to 1.60; p = 0.02) fold
higher plasma concentrations among participants who reported
incomplete versus 100% adherence respectively (Table 3). No
significant differences were observed in the remaining
biomarkers or in the CD4+/CD8+ T-cell ratio between partici-
pants who reported incomplete versus 100% adherence at the
eight-month visit (Table 3).
In the sensitivity analysis, when the definition of incomplete
ART adherence was expanded to include any report of <100%
adherence at any of the one, four or eight months visits, the
participants categorized to have incomplete adherence had
1.10 (1.01 to 1.19; p = 0.02) fold higher plasma concentrations
Table 1. (Continued)
Characteristic
Incomplete
adherence n=109
100%
Adherence
n=1518
n (%) or median (IQR)
Region
Africa 16 (15) 341 (22)
Latin America 37 (34) 382 (25)
Europe/Israel 26 (24) 511 (34)
United States 19 (17) 123 (8)
Australia 2 (2) 36 (2)
Asia 9 (8) 125 (8)
HBV infection 0 (0) 44 (3)
HCV infection 4 (4) 51 (3)
BMI at baseline (kg/
m2)
24.4 (22.3, 29.3) 24.5 (22.0, 27.8)
Current smoker
(baseline)
43 (39) 476 (32)
CD4+ T cells at
baseline (cells/
mm3)
658 (596, 760) 649 (585, 769)
HIV RNA at baseline
(copies/mL)
9803 (3017, 34,178) 13,411 (3382, 42,717)
ART, antiretroviral therapy; BMI, body mass index; HBV, hepatitis B
virus; HCV, hepatitis C virus; IDU, injection drug users; INSTI, inte-
grase strand-transfer inhibitor; IQR, inter-quartile range; MSM, men
who have sex with men; NNRTI, non-nucleoside reverse transcriptase
inhibitor; PI, protease inhibitor; VL, viral load.
aAll participants received a dual nucleoside/nucleotide reverse tran-
scriptase inhibitor backbone; bINSTI-based therapy was raltegravir
based; only one participant was prescribed elvitegravir in the 100%
adherence group.
Table 2. Biomarkers of inflammation, immune activation, vas-
cular inflammation and CD4+/CD8+ T-cell ratio before and
eight-months after ART initiation (sample restricted to those
with values at both time points in the immediate arm of
START)
Biomarker
Baseline
Eight-month
visit
p-valuena Median (IQR) Median (IQR)
IL-6 (pg/mL) 1626 1.39 (0.98, 2.15) 1.24 (0.84, 1.94) <0.0001
hsCRP
(lg/mL)
1626 1.86 (0.76, 4.15) 1.82 (0.74, 4.66) 0.005
SAA (mg/L) 1626 4.8 (2.6, 9.1) 3.8 (2.1, 7.8) <0.0001
IL-27 (pg/mL) 1626 244 (123, 506) 240 (111, 534) 0.1
sICAM
(ng/mL)
1626 543 (424, 693) 477 (369, 611) <0.0001
sVCAM
(ng/mL)
1626 719 (556, 928) 555 (439, 884) <0.0001
D-dimer
(lg/mL)
1616 0.32 (0.22, 0.49) 0.27 (0.19, 0.43) <0.0001
CD4+/CD8+
ratio
1606 0.66 (0.49, 0.89) 0.98 (0.74, 1.28) <0.0001
p-values are from Wilcoxon Signed rank test, based on individuals who
had available biomarker data at both baseline and eight month visits.
ART, antiretroviral therapy; hsCRP, high-sensitivity C-reactive protein;
IL-27, interleukin 27; IL-6, interleukin 6; IQR, interquartile range; SAA,
serum amyloid A protein; sICAM, soluble intercellular adhesion mole-
cule-1; sVCAM, soluble vascular adhesion molecule-1.
aSample sizes may be smaller than what is reported in Table 1 due to
missing data at the eight-month visit.
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of IL-6, 1.01 (0.94 to 1.08; p = 0.85) fold higher plasma con-
centrations of d-dimer, and 1.15 (0.99 to 1.33; p = 0.06) fold
higher plasma concentrations of SAA at the eight-month visit,
respectively, compared to participants who reported 100%
adherence (Table 4, adjusted analysis). No significant differ-
ences in the other biomarkers or the CD4+/CD8+ T-cell ratio
were observed using this broader definition of incomplete
adherence (Table 4). When participants who reported taking
“none of my pills” (n=11) were removed from the analysis,
those with imperfect adherence had 1.11 (0.98 to 1.25;
p = 0.10) fold higher plasma concentrations of IL-6 (in an
adjusted analysis) and 0.86 (0.75 to 0.99; p = 0.03) fold lower
plasma concentrations of d-dimer when compared with partici-
pants who reported 100% adherence (unadjusted analysis,
results of the adjusted analysis were not significant – data not
shown).
4 | DISCUSSION
This study identified an inverse association between ART
adherence and plasma concentrations of IL-6 in participants
who achieved virologic suppression after eight months of ART
in the immediate arm of the START study. However, it did not
confirm this association for D-dimer as originally hypothe-
sized. In addition, this analysis describes a potential novel sim-
ilar association with SAA in the exploratory analyses. These
results for IL-6, while moderate in size (i.e. 12% difference),
are consistent with the range of concentrations from previous
studies (including SMART and START) where IL-6 was found
to be predictive of mortality and adverse events in HIV
[24,26,32,33]. They are also consistent with prior findings
[18-20] evaluating the association of suboptimal adherence
and inflammation, and expand it to individuals who initiated
ART with high CD4+ T-cell counts (>500 cells/mm3). This is of
particular importance given the significant associations of
heightened systemic inflammation and coagulopathy with
increased risk for AIDS events, SNAEs and death observed in
the START study [21]. Collectively, our findings re-emphasize
the biologic importance that optimal adherence could have on
maximizing the therapeutic benefit of ART, even in individuals
who start ART with high CD4+ T cells, in whom advanced
immunodeficiency has not been established [34].
As noted, our results confirm previous observations in
diverse populations where incomplete adherence had a similar
association with inflammation and immune activation. For
example, data from the MACS cohort demonstrated that
<100% (and in particular <85% adherence) self-reported
adherence to ART (using four-day and six-month recall) was
associated with 11% to 21% higher plasma concentrations of
IL-10, tumour necrosis factor-alpha, IL-6, IL-2, interferon-
gamma and CRP in 2816 person-visits from 912 virologically
suppressed (<50 copies/mL) men living with HIV [18]. Simi-
larly, an analysis of 270 treatment-na€ıve individuals who
achieved viral suppression (<400 copies/mL) after six months
of ART in Uganda found that a 10% increase in average
adherence, measured using the Medication Event Monitoring
System (MEMS), was associated with a 3% to 15% decrease
in plasma levels of soluble CD14 (p = 0.03), D-dimer
(p = 0.02) and IL-6 (p < 0.0001) [19]. Lastly, similar findings
were identified in the SMART study, where <100% self- T
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reported ART adherence (using seven-day recall) was associ-
ated with 9% and 11% higher plasma concentrations of IL-6
(p = 0.02) and D-dimer (p = 0.03) respectively in over 2700
HIV-infected participants who were virologically suppressed
(<200 copies/mL) upon enrolment [20]. Of note, all of these
associations (and those in our current study), remained signifi-
cant after adjusting for available demographic and clinical
covariates that have previously been associated with biomark-
ers of inflammation and coagulopathy. In addition, these stud-
ies were conducted in diverse observational and research
cohorts vastly representative of real-world clinical populations.
This is in comparison to recent studies in participants who
had very long-standing and sustained viral suppression, where
cumulative drug exposure was not associated with biomarkers
of inflammation [35].
While treated HIV infection has been associated with per-
sistent elevations of IL-6 and CRP in multiple cohorts and clin-
ical trials [5,26,36], the role of SAA in this setting remains
poorly understood. Although the association between SAA and
suboptimal adherence was identified in the exploratory analy-
sis of additional biomarkers, a p = 0.35 in the O’Brien test
suggests that the null hypothesis of no differences in biomark-
ers by adherence category could not be rejected, thus there
should be caution in interpreting these results. However,
these findings are biologically consistent with our IL-6 results
and suggest that variable ART adherence may be most
impactful through a unified inflammatory pathway that
involves these biomarkers (and could possibly also include
CRP), in comparison to other networks of inflammation or
defective adaptive immunity (i.e. CD4+/CD8+T-cell ratio) that
are associated with adverse outcomes in HIV infection
[34,37]. SAA has been traditionally regarded as an acute
phase reactant lipoprotein [38], which is mainly synthesized by
the liver and has been found to correlate with CRP in the set-
ting of acute [39] and chronic inflammation [40], and to pre-
dict cardiovascular outcomes [41]. Recently, it has been
proposed that SAA could be a mechanistic link between obe-
sity and cardiovascular disease, by virtue of promoting inflam-
mation at the level of the adipose tissue, leading to insulin
resistance [42,43] and dyslipidemia [42], and that it can
improve with weight loss [44] and statin therapy [42,45]. In
the HIV arena, SAA has been proposed as a marker of very
acute HIV infection and to have early antiviral properties [46].
Comparatively, SAA has been found to correlate with other
biomarkers of inflammation including CRP, IL-6 and IL-8 in
chronic HIV infection [47], and with the development of
opportunistic disease [48], but not mortality or early treat-
ment discontinuation, in the SMART study [26]. In START,
SAA was also found to be strongly correlated with biomarkers
of vascular inflammation including hsCRP, sICAM and sVCAM,
which translated into an increased risk of AIDS-related events
in participants who had higher concentrations of SAA [24].
Further studies to confirm our findings, and to better under-
stand the clinical associations between ART adherence and
SAA in treated HIV infection, are required.
In contrast to our findings in START and other cohorts,
recent studies that have evaluated incomplete ART adherence
by means of alternative dosing of oral regimens, such as four
days on/three days off [49] or weekends off ART [50] in virolog-
ically suppressed adults and children, have not demonstrated
any impact in biomarkers of inflammation or coagulopathy. In
fact, D-dimer showed a trend towards lower plasma concentra-
tions in children and young adults randomized to weekends off
efavirenz-based ART in one of these studies [50], which was
unexpected, but similar to our findings of lower D-dimer in sub
optimally adherent participants in START. Among the possible
explanations for these different findings is that the patients
selected for inclusion in these studies constituted a population
with long-standing virologic suppression, which differs from the
study populations evaluated in previous studies where adher-
ence and inflammation were associated [18-20]. Alternatively,
the periods off ART (and their consequential decrease in drug
exposure) that were instituted in these studies were pre-
dictable and cyclic, in comparison with the more erratic and
irregular variations in ART adherence that are expected (and
have been observed) in clinical and research cohorts. These dif-
ferences emphasize the need for further research in this area,
including the analysis of biomarkers of inflammation and coagu-
lopathy in randomized studies where participants have been
assigned to less-than-daily dosing (NCT03256422) [51] or have
been simplified to maintenance with two-drug ART regimens.
Several mechanisms to explain our observed association
between incomplete ART adherence and higher inflammation
have been proposed. Among them are the possibility of subclini-
cal viral replication below the limit of detection of conventional
assays or the occurrence of intermittent episodes of measurable
(but missed) viraemia that lead to bursts of inflammation, but
which cannot be captured in the time points between clinical or
research visits in individuals who are not fully adherent [18]. An
additional potential explanation could be that patients who are
100% adherent to their ART could also be more adherent to
non-HIV medications with an anti-inflammatory effect (i.e. statins
or aspirin), and that they could also practice overall healthier
behaviours that lead to a more pronounced reduction in inflam-
mation (i.e. less likely to smoke, more likely to exercise and eat a
healthier diet). While our analysis controlled for smoking and
BMI, we did not capture any additional information on these or
other potential confounding factors associated with a healthier
lifestyle, which may also be associated with lower levels of
inflammation. Future studies focused on interventions aimed at
reducing chronic residual inflammation in treated HIV infection
should include measures of ART adherence and determinants of
a healthy lifestyle in order to fully understand these interactions.
Along with the possible explanatory mechanisms, the poten-
tial clinical findings derived from our observations merit speci-
fic considerations. As ART has become easier to take in the
modern era, it has also become more pharmacologically forgiv-
ing, allowing for as low as 80% to 85% adherence to achieve
and sustain an undetectable viral load [52]. Thus, achieving
and sustaining viral suppression using clinically available assays
(i.e. <50 or <20 copies/mL) is not a surrogate for perfect
adherence. Of note, our findings were attenuated when the
small subset of participants who reported full non-adherence
in the last seven days were removed, although the directional-
ity of the association remained unchanged. This finding is simi-
lar to previous observations in the MACS, where <85%
adherence (vs. 85% to 99% adherence) was the main driver of
heightened inflammation for most biomarkers. To date, the
biological and clinical consequences that develop in the range
between “suppressive” and optimal adherence have only been
partially evaluated. In particular, whether an improvement in
ART adherence, through a proven behavioural intervention or
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by means of easier dosing (i.e. use of long-acting injectable
ART), can be translated into a reduction in inflammation in the
setting of virologic suppression remains unknown, but should
be evaluated. In this context, an increase in ART adherence
(even if not perfect) that is coupled with a reduction in inflam-
mation would be highly clinically impactful, as it could modify
our current treatment focus and encourage patients and pro-
viders to strive for the highest possible adherence, especially
if all the negative consequences of incomplete adherence are
fully recognized.
Our study offers several strengths that should be empha-
sized. First, it is based on longitudinal data from a large,
racially/ethnically diverse sample size enrolled within a multi-
national clinical trial. Second, the biomarker profile that was
analysed is broad and includes markers of vascular inflamma-
tion, which had not been previously evaluated in the context
of suboptimal ART adherence beyond viral suppression. Lastly,
we were able to confirm the association between adherence
and inflammation in individuals with suppressed HIV viraemia
and early HIV disease and preserved CD4+ T-cell counts.
Among the limitations of our analysis are that the size of the
association is moderate in magnitude, and that we were
unable to assess any potential association of suboptimal ART
adherence with clinical endpoints, mostly due to the overall
low frequency of events in the START study. In addition, self-
reported adherence has limitations such as recall and social
desirability bias [53], which could have lessened the effect size
of our findings. Furthermore, higher adherence, in the context
of a clinical trial, may also reflect an overall healthier life style
[54]. Similarly, this analysis could not determine whether the
association between ART adherence and inflammation
extended beyond the eight-month time point, or whether it
extended to changes in biomarkers of monocyte activation
(not evaluated in START). Finally, we could not assess whether
our findings were ART-class specific given the small propor-
tion of participants on an integrase-based regimen. Future
studies focusing on objective measures of ART adherence and
their association with clinical endpoints are needed, including
the effects of the duration and severity of non-adherence on
chronic inflammation in PLHIV.
5 | CONCLUSIONS
In summary, we identified an association between incomplete
ART adherence and systemic inflammation in the setting of
viral suppression in PLHIV who initiated treatment with high
CD4+ T-cell counts. This confirms previous findings in other
cohorts and suggests it may be important to optimize adher-
ence even during virologic suppression as a possible interven-
tion to improve residual inflammation and reduce morbidity
and mortality in HIV disease.
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